Open AccessMucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update
Author(s) -
LeBlanc Jean Guy,
Aubry Camille,
CortesPerez Naima G.,
de Moreno de LeBlanc Alejandra,
Vergnolle Nathalie,
Langella Philippe,
Azevedo Vasco,
Chatel JeanMarc,
Miyoshi Anderson,
BermúdezHumarán Luis G.
Publication year - 2013
Publication title -
fems microbiology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 151
eISSN - 1574-6968
pISSN - 0378-1097
DOI - 10.1111/1574-6968.12159
Subject(s) - lactococcus lactis , lactococcus , probiotic , biology , genetically modified organism , bacteria , lactic acid , genetically engineered , microbiology and biotechnology , recombinant dna , computational biology , genetics , gene
Lactic acid bacteria ( LAB ) represent a heterogeneous group of microorganisms naturally present in many foods and those have proved to be effective mucosal delivery vectors. Moreover, some specific strains of LAB exert beneficial properties (known as probiotic effect) on both human and animal health. Although probiotic effects are strain‐specific traits, it is theoretically possible, using genetic engineering techniques, to design strains that can exert a variety of beneficial properties. During the two past decades, a large variety of therapeutic molecules has been successfully expressed in LAB , and although this field has been largely reviewed in recent years, approximately 20 new publications appear each year. Thus, the aim of this minireview is not to extensively assess the entire literature but to update progress made within the last 2 years regarding the use of the model LAB L actococcus lactis and certain species of lactobacilli as live recombinant vectors for the development of new safe mucosal vaccines.